Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.63 |
| ▸ | PDE6D | O43924 | 2/20 | 0.63 |
| ▸ | PDE6A | P16499 | 2/20 | 0.63 |
| ▸ | PDE6G | P18545 | 2/20 | 0.63 |
| ▸ | PDE6B | P35913 | 2/20 | 0.63 |
| ▸ | PDE6C | P51160 | 2/20 | 0.63 |
| ▸ | PDE6H | Q13956 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252471 | 0.91 | PDE5A (0.76) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL10248559 | 0.79 | PDE5A (0.59) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL10248567 | 0.79 | PDE5A (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL867660 | 0.77 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL867299 | 0.77 | PDE5A (0.81) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL10250013 | 0.76 | PDE5A (0.77) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16229846 | 0.75 | PDE5A (0.70) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7889438 | 0.73 | PDE5A (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL10251959 | 0.73 | PDE5A (0.65) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL10250024 | 0.71 | PDE5A (0.43) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076732-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076732-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | PDE5A 2/4885PDE6D 51/4885PDE6A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.